{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on the Impact of Hyperosmolar Prime Solution on Cardiac Surgery Associated Acute Kidney Injury"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In this double-blind, prospective randomised controlled trial, 200 patients aged \u226565 years scheduled for routine cardiac surgery with cardiopulmonary bypass at a single tertiary teaching hospital in Sweden were randomised (1:1)"
      },
      "Participants": {
        "score": 2,
        "evidence": "200 patients aged \u226565 years scheduled for routine cardiac surgery with cardiopulmonary bypass at a single tertiary teaching hospital in Sweden"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised (1:1) to receive either a hyperosmolar prime solution (Ringer\u2019s acetate 1000 mL + 400 mL Mannitol + sodium chloride 40 mL + heparin 2 mL, 966 mOsmol) or a control solution (Ringer\u2019s acetate 1400 mL + heparin 2 mL, 388 mOsmol)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate whether a Ringer\u2019s acetate-based priming solution with Mannitol and sodium chloride increases the risk of cardiac surgery associated acute kidney injury (CSA-AKI)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was CSA-AKI, defined by KDIGO criteria, assessed on day 1 in the ICU and day 3 postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 2,
        "evidence": "In this double-blind, prospective randomised controlled trial"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "200 patients aged \u226565 years scheduled for routine cardiac surgery"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of the 195 patients analysed (98 Mannitol, 97 Ringer)"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "the incidence of CSA-AKI was 2.6% on day 1 and 5.6% on day 3. No significant intergroup differences in serum creatinine levels were observed."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT05914896."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}